FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Johnson Bankole A.
2. Issuer Name and Ticker or Trading Symbol

ADIAL PHARMACEUTICALS, INC. [ ADIL ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)

1001 RESEARCH PARK BLVD., SUITE 100
3. Date of Earliest Transaction (MM/DD/YYYY)

10/2/2019
(Street)

CHARLOTTESVILLE,, VA 22911
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/2/2019    A    3187  A $0  351055  D   
Common Stock                 40463  I  Medico-Trans Company, LLC (1)
Common Stock                 848336  I  En Fideicomiso De Mi Vida 11/23/2010 (Trust) (2)
Common Stock                 93000  I  En Fidecomiso de Todos Mis Suenos Grantor Retained Annuity Trust dated June 27, 2017 (2)
Common Stock                 22320  I  En Fideicomiso De Mis Suenos 11/23/2010 (Trust) (2)
Common Stock                 10000  I  De Mi Amor 11/23/2010 (Trust) (2)
Common Stock                 4650  I  Efunbowale Johnson (3)
Common Stock                 1395  I  Ade Johnson (3)
Common Stock                 1395  I  Lola Johnson (3)
Common Stock                 930  I  Lina Tiouririne (3)
Common Stock                 930  I  Aida Tiouririne (3)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Medico-Trans Company, LLC is controlled by Bankole Johnson.
(2)  Dr. Johnson is the trustee of each of these trusts.
(3)  Dr. Johnson has a voting proxy on this person's behalf that entitles him to vote these shares.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Johnson Bankole A.
1001 RESEARCH PARK BLVD., SUITE 100
CHARLOTTESVILLE,, VA 22911

X Chief Medical Officer

Signatures
/s/ Bankole Johnson 10/4/2019
**Signature of Reporting Person Date


Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Adial Pharmaceuticals Charts.
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Adial Pharmaceuticals Charts.

Adial Pharmaceuticals, Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
Monday 22 April 2024 (2 weeks ago) • GlobeNewswire Inc.
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Wednesday 10 April 2024 (3 weeks ago) • GlobeNewswire Inc.
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
Tuesday 2 April 2024 (1 month ago) • GlobeNewswire Inc.
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
Saturday 2 March 2024 (2 months ago) • GlobeNewswire Inc.
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
Thursday 29 February 2024 (2 months ago) • GlobeNewswire Inc.
Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
Wednesday 14 February 2024 (3 months ago) • GlobeNewswire Inc.
Form 424B5 - Prospectus [Rule 424(b)(5)]
Friday 26 January 2024 (3 months ago) • Edgar (US Regulatory)
Form EFFECT - Notice of Effectiveness
Thursday 25 January 2024 (3 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Friday 19 January 2024 (3 months ago) • Edgar (US Regulatory)
Adial Announces Appointment of Tony Goodman as Chief Operating Officer
Friday 19 January 2024 (3 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Wednesday 17 January 2024 (4 months ago) • Edgar (US Regulatory)